Probiotic Detection and Persistence Study

Detection and Persistence of a Product Containing L. Helveticus R-0052, L. Casei HA-108, B. Breve HA-129, B. Longum R-0175 and S. Thermophilus HA-110 in Healthy Adults: an Open-label Pilot Study.

The aims of this study are to determine how long it takes for the strains of a probiotic formulation to be detected in feces after the start of an intervention, how long they persist after the end of the intervention, and the associations between detection and persistence with total gut transit time.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Biological: Probiotic Strains

Detailed Description

This is a 10-week interventional, open-label pilot study designed to evaluate the detection and persistence of L. helveticus R-0052, L. casei NI319, B. breve NI337, and B. longum R-0175 strains in feces of healthy adults following the start and the end of IP intervention, respectively. This study will have an initial baseline period (4 weeks), a probiotic intervention (2 weeks) and a washout period (4 weeks). Participants will complete daily questionnaires regarding stool frequency, time of stool collections, and IP intake. A weekly Gastrointestinal Symptom Rating Scale (GSRS) questionnaire will be administered. Transit time will be assessed using radiopaque markers.

• Study Type: Interventional
• Enrollment (Actual): 31
• Phase: Early Phase 1

Contacts and Locations

Study Locations

• United States
  • Florida
    • Gainesville, Florida, United States, 32611
      • Food Science and Human Nutrition Department

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 51 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Healthy adults ≥ 18 to < 55 years of age.
• Habitually produces at least one bowel movement per day.
• Willingness to maintain their usual diet and exercise patterns throughout the study.
• Able to provide written informed consent in English.
• Willing to provide stools and complete questionnaires, records, and diaries associated with the study and to complete all study visits.
• Willingness to discontinue consumption of probiotics and fermented products (e.g. yogurts, kombucha, fermented pickles and other fermented foods with live, active cultures) and probiotic supplements.

Exclusion Criteria:

• Elite athletes or long-distance runners.
• Concurrent consumption of fermented foods or probiotics. However, individuals will be eligible for participation after a four (4) week wash-out period.
• Known to be pregnant (self-disclosure) or breastfeeding or planning on becoming pregnant in the next 2 months.
• Use of antibiotic drugs (e.g., neomycin, rifaximin) within 1 month of the screening visit. The screened participant would be eligible to participate four (4) weeks after completing their course of antibiotics (washout period).
• Use of other investigational products within 3 months of the screening visit.
• Previously or are currently being treated for any previously or currently being treated for any intestinal disease or condition such as IBS, Crohn's disease, ulcerative colitis, celiac disease, or gastrointestinal cancer.
• Immune disorders or with possible immune deficient status (e.g. due to surgery).
• Milk or soy allergy.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Healthy Adults; Healthy adults will be given probiotic strains to evaluate the detection and persistence of the strains in the participant's feces.	Biological: Probiotic Strains; A commercial product containing L. helveticus R0052, L. casei HA-108, B. breve HA-129, and B. longum R0175 and S. thermophilus HA-110 be given to healthy adults across a 10-week open label pilot study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in time to detection of probiotic strains	using strain-specific qPCR assays.	Day 1; Day 2; Day 3, Day 4, Day 7, Day 10
Change in time to non-detection (persistence) of probiotic strains	using strain-specific qPCR assays.	Day 14, Day 15, Day 16, Day 17, Day 18, Day 21, Day 24, Day 28, Day 35, Day 42

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Whole gut transit time	Whole gut transit time measured by radiopaque marker recovery in intervention stools	Day 1, Day 2, Day 3, Day 4

Collaborators and Investigators

• Sponsor: University of Florida
• Collaborators: Lallemand Health Solutions, Inc.
• Investigators: Principal Investigator: Wendy Dahl, University of Florida

Study record dates

Study Major Dates

• Study Start (Actual): December 6, 2019
• Primary Completion (Actual): February 26, 2020
• Study Completion (Actual): December 31, 2020

Study Registration Dates

• First Submitted: August 20, 2019
• First Submitted That Met QC Criteria: August 21, 2019
• First Posted (Actual): August 22, 2019

Study Record Updates

• Last Update Posted (Actual): January 19, 2021
• Last Update Submitted That Met QC Criteria: January 14, 2021
• Last Verified: January 1, 2021

More Information

Terms related to this study

• Keywords: probiotic; gut transit time
• Other Study ID Numbers: IRB201902202; OCR26142 (Other Identifier: UF OnCore); AGR00015606 (Other Identifier: UFIRST)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No